About the study
Every five years, CTSU brings together updated data on each woman randomised into all trials of the treatment of operable breast cancer. The EBCTCG process was initiated in 1983 and the first cycle collected data for hormonal and cytotoxic therapy in 1985. The collaboration was extended in the 1990s to all aspects of early breast cancer management and its results informed the year 2000 NIH consenus development conference on the treatment of early breast cancer. The 2005 report on chemotherapy and endocrine therapy shows the substantial effects on 15-year survival of the chemotherapy regimens (such as about 6 months of FAC or FEC in women aged <70) and hormonal regimens (such as at least 5 years of tamoxifen in women with ER+ disease) that were being tested in the 1980s. The 2005 report on surgery and radiotherapy shows that treatments that substantially improve local control have little effect on breast cancer mortality during the first few years, but definite effects by 15 years.
Recent publications are listed below, while the sixth cycle of data collection is in progress.
Early Breast Cancer Trialists’ Collaborative Group, Writing committee, Peto R, Godwin J, Davies C, Gray R, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012; 379(9814): 432-44.
Early Breast Cancer Trialists' Collaborative Group, Writing committee, Davies C, Peto R, Gray R, Clarke M, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011; 378(9793): 771-84.
Early Breast Cancer Trialists' Collaborative Group, Writing committee, Darby S, McGale P, Correa C, Taylor C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer mortality: meta analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707-16.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28(3): 509-18.